Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maarten Boers

Showing results (301-310 of 308) with videos related to

Pageof 31
Sort By:
You have reached the last page of results.This site can display upto 308 results.
Seminars in Arthritis and Rheumatism|July 13, 2021
Improving benefit-harm assessment of glucocorticoid therapy incorporating the patient perspective: The OMERACT glucocorticoid core domain setJoanna Tieu, Jonathan Tl Cheah, Rachel J Black, et al.
Annals of the Rheumatic Diseases|February 5, 2011
American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trialsDavid T Felson, Josef S Smolen, George Wells, et al.
Arthritis and Rheumatism|February 5, 2011
American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trialsDavid T Felson, Josef S Smolen, George Wells, et al.
The Journal of Rheumatology|February 19, 2013
A delphi exercise to identify characteristic features of gout - opinions from patients and physicians, the first stage in developing new classification criteriaRebecca L Prowse, Nicola Dalbeth, Arthur Kavanaugh, et al.
BMJ Open|September 7, 2019
Zoledronate in the prevention of Paget's (ZiPP): protocol for a randomised trial of genetic testing and targeted zoledronic acid therapy to prevent <i>SQSTM1</i>-mediated Paget's disease of boneOwen Cronin, Laura Forsyth, Kirsteen Goodman, et al.
Annals of the Rheumatic Diseases|March 8, 2017
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 updateJosef S Smolen, Robert Landewé, Johannes Bijlsma, et al.
Annals of the Rheumatic Diseases|January 24, 2020
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 updateJosef S Smolen, Robert B M Landewé, Johannes W J Bijlsma, et al.
The Lancet. Rheumatology|May 9, 2022
Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studiesLaura Boekel, Eileen W Stalman, Luuk Wieske, et al.
Pageof 31

Showing results (301-310 of 308) with videos related to

Sort By:
Pageof 31
You have reached the last page of results.This site can display upto 308 results.
Seminars in Arthritis and Rheumatism|July 13, 2021
Improving benefit-harm assessment of glucocorticoid therapy incorporating the patient perspective: The OMERACT glucocorticoid core domain setJoanna Tieu, Jonathan Tl Cheah, Rachel J Black, et al.
Annals of the Rheumatic Diseases|February 5, 2011
American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trialsDavid T Felson, Josef S Smolen, George Wells, et al.
Arthritis and Rheumatism|February 5, 2011
American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trialsDavid T Felson, Josef S Smolen, George Wells, et al.
The Journal of Rheumatology|February 19, 2013
A delphi exercise to identify characteristic features of gout - opinions from patients and physicians, the first stage in developing new classification criteriaRebecca L Prowse, Nicola Dalbeth, Arthur Kavanaugh, et al.
BMJ Open|September 7, 2019
Zoledronate in the prevention of Paget's (ZiPP): protocol for a randomised trial of genetic testing and targeted zoledronic acid therapy to prevent <i>SQSTM1</i>-mediated Paget's disease of boneOwen Cronin, Laura Forsyth, Kirsteen Goodman, et al.
Annals of the Rheumatic Diseases|March 8, 2017
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 updateJosef S Smolen, Robert Landewé, Johannes Bijlsma, et al.
Annals of the Rheumatic Diseases|January 24, 2020
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 updateJosef S Smolen, Robert B M Landewé, Johannes W J Bijlsma, et al.
The Lancet. Rheumatology|May 9, 2022
Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studiesLaura Boekel, Eileen W Stalman, Luuk Wieske, et al.
Pageof 31